Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

Pharmacology Biochemistry and Behavior

Volumn 95, Issue 4, 2010, Pages 434-442

  El Alfy, Abir T ^a   Ivey, Kelly ^a   Robinson, Keisha ^a   Ahmed, Safwat ^b,c   Radwan, Mohamed ^b   Slade, Desmond ^b   Khan, Ikhlas ^a,b   ElSohly, Mahmoud ^a,b   Ross, Samir ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c Suez Canal University   (Egypt)

Author keywords

8 Tetrahydrocannabinol; 9 Tetrahydrocannabinol; Antidepressant; Cannabichromene; Cannabidiol; Cannabigerol; Cannabinol; Cannabis; Forced swim test; Locomotor activity; Tail suspension test

Indexed keywords

CANNABICHROMENE; CANNABIDIOL; CANNABIGEROL; CANNABINOL; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DESIPRAMINE; DRONABINOL; FLUOXETINE; ANTIDEPRESSANT AGENT; CANNABINOID; DELTA-8-TETRAHYDROCANNABINOL; DRUG DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ISOLATION; DRUG STRUCTURE; FORCED SWIMMING TEST; IMMOBILIZATION STRESS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CATALEPSY; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; HYPOTHERMIA; IMMOBILIZATION; RANDOMIZATION; SWIMMING; TONIC IMMOBILITY;

CANNABIS; CANNABIS SATIVA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CANNABIDIOL; CANNABINOIDS; CANNABIS; CATALEPSY; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB SUSPENSION; HYPOTHERMIA; IMMOBILITY RESPONSE, TONIC; MALE; MICE; RANDOM ALLOCATION; SWIMMING; TETRAHYDROCANNABINOL;

EID: 77952551436     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.03.004     Document Type: Article

References (69)

1. Ahmed S.A., Ross S.A., Slade D., Radwan M., Zulfiqar F., ElSohly M.A. Cannabinoid ester constituents from high potency Cannabis sativa L. J Nat Prod 2008, 71:536-542.
2. Ahmed S.A., Ross S.A., Slade D., Radwan M.M., Khan I.A., ElSohly M.A. Absolute configuration of cannabichromene derivatives from high potency Cannabis sativa. Tetrahedron Lett 2008, 49:6050-6053.
3. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D., Brandi I., et al. Molecular targets for cannabidiol and its synthetic analogs: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001, 134:845-852.
4. Booker L., Naidu P.S., Razdan R.S., Mahadevan A., Lichtman A.H. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alc Dependence 2009, 105:42-47.
5. Bourin M., Chenu F., Ripoll N., David D.J.P. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005, 164:266-269.
6. Bovassa G.B. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001, 158:2033-2037.
7. 9-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol 1997, 323:R3-R4.
8. Carrier E.J., Auchampach J.A., Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006, 103:7895-7900.
9. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., et al. Cannabinoid structure activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993, 265:218-226.
10. Crowley J.J., Jones M.D., O'Leary O.F., Lucki I. Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem and Behav 2004, 78:269-274.
11. Crowley J.J., Blendy J.A., Lucki I. Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 2005, 183:257-264.
12. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
13. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 2003, 54:49-58.
14. Cryan J.F., Page M.E., Lucki I. Differential behavior effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. J Psychopharmacology 2005, 182:335-344.
15. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav R 2005, 29:571-625.
16. Devane W., Hanus L., Breuer A., Pertwee R., Stevenson L., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science 1992, 258:1946-1949.
17. Dinh T., Carpenter D., Leslie F., Freund T., Katona I., Sensi S., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. PNAS 2002, 99:10819-10824.
18. ElSohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005, 78:539-548.
19. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockage of anandamide hydrolysis. PNAS 2005, 102:18620-18625.
20. Gong J., Onaivi E., Ishigura H.L.Q., Tagliaferro P., Brusco A., Uhi G. Cannabinoid CB2 receptors immunohistochemical localization in rat brain. Brain Res 2006, 1071(1):10-23.
21. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist Rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005, 57:261-267.
22. Griffin G., Wray E.J., Rorrer W.K., Crocker P.J., Ryan W.J., Saha B., et al. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. Br J Pharmacol 1999, 126:1575-1584.
23. Grinsponn L., Balkar J. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998, 30:171-177.
24. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Drug Disposition 2003, 42:327-360.
25. Gruber A., Pope H., Brown M. Do patients use marijuana as an antidepressant?. Depression 1996, 4:77-80.
26. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15(6):593-599.
27. Hill M., Miller G., Ho W., Gorzalka B., Hillard C. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41(2):48-53.
28. Jarvis K., DelBello M.P., Mills N., Elman I., Strakowski S.M., Adler C.M. Neuroanatomic comparison of bipolar adolescents with and without cannabis use disorders. J Child Adolesc Psychopharmacol 2008, 18:557-563.
29. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115:3104-3116.
30. Johns A. The psychiatric effects of cannabis. Br J Psychiatry 2001, 178:116-122.
31. Koethe D., Llenos I., Dulay J., Hoyer C., Torrey E., Leweke F., et al. Expression of CB1 cannabinoid receptor in the anterior cinguate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007, 114(8):1055-1063.
32. Lee K.S., Clough A.R., Jaragba M.J., Conigrave K.M., Patton G.C. Heavy cannabis use and depressive symptoms in three Aboriginal communities in Arnhem Land, Northern Territory. Med J Aust 2008, 188:605-608.
33. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008, 13(2):274-275.
34. Liu X., Gershenfeld H.K. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biol Psychiatry 2001, 49:575-581.
35. Matsuda L., Lolait S., Brownstein M., Young A., Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
36. Mombereau C., Kaupmann K., Froestl W., Sansig G., van der Putten H., Cryan J.F. Genetics and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety and antidepressant-like behavior. Neuropsychopharmacology 2004, 29:1050-1062.
37. Naidu P.S., Yarvel S.A., Ahn K., Cravatt B.F., Martin B.R. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 2007, 192:65-70.
38. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004, 279:5298-5305.
39. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990, 253:1002-1009.
40. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999, 6:635-664.
41. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005, 76:1307-1324.
42. Pertwee R.G. Cannabinoid pharmacology: the first 66years. Br J Pharmacol 2006, 147:S163-S171.
43. 9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 2007, 150:586-594.
44. Porsolt R.D., Lenegre A. Behavioral models of depression. Experimental approaches to anxiety and depression 1992, 73-85. Wiley, London. J. Eliott, D. Heal, C. Mardesen (Eds.).
45. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
46. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
47. Radwan M.M., Ross S.A., Slade D., Ahmed S., Zulfiqar F., ElSohly M.A. Isolation and characterization of new cannabis constituents from high potency variety. Planta Medica 2008, 74:267-272.
48. Radwan M., ElSohly M.A., Slade D., Ahmed S.A., Wilson L., El-Alfy A.T., et al. Non- cannabinoid constituents from a high potency Cannabis sativa variety. J Nat Prod 2008, 69:2627-2633.
49. Radwan M.M., ElSohly M.A., Slade D., Ahmed S.A., Ross S.A. Biologically active cannabinoids from high potency Cannabis sativa. J Nat Prod 2009, 72:906-911.
50. Renard C.E., Dailly E., David D.J.P., Hascoet M., Bourin M. Monoamine metabolism changes following the mouse forced swim test but not the tail suspension test. Fundam Clin Pharmacol 2003, 17:449-455.
51. Ross S.A., ElSohly M.A. Constituents of Cannabis sativa L. XXVII. A review of the natural constituents 1980-1994. Zagazig. J Pharm Sci 1995, 4:1-10.
52. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res 2005, 30:1037-1043.
53. Rutkowska M., Jachimezuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 2004, 61:165-167.
54. Shearman L., Rosko K., Fleicher R., Wang J., Xu S., Tong X., et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003, 14(8):573-582.
55. Sim L.J., Hampson R.E., Deadwyler S.A., Childers S.R. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S] GTPS autoradiography in rat brain13. J Neurosci 1996, 16:8057-8066.
56. Skolnick P., Legutko B., Li X., Bymaster F. Current perspectives on the development of non biogenic amine-based antidepressants. Pharmacol Res 2001, 43:411-412.
57. Steru L., Chermat R., Thierry B., Simon P., Porsolt R. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
58. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonylglycerol, a possible endogenous receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
59. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998, 59:347-352.
60. Thierry B., Steru L., Simon P., Porsolt R.D. The tail suspension: ethical considerations. Psychopharmacology 1986, 90:284-285.
61. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007, 150:613-623.
62. Turner C.E., ElSohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of natural constituents. J Nat Prod 1980, 43:169-170.
63. Tzavara E., Perry K., Rodriguez D., Bymaster F., Nomikos G. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 2001, 426(3):R3-R4.
64. Tzavara E., Davis R., Perry K., Li X., Salhoff C., Bymaster F., et al. The CB1 receptor antagonist SR14176 selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic action. Br J Pharmacol 2003, 138(4):544-553.
65. Valjent E., Pages C., Rogard M., Besson M.J., Maldonado R., Caboche J. Delta-9 tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur J Neurosci 2001, 14(2):342-352.
66. van Rossum I., Boomsma M., Tenback D., Reed C., van Os J. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis 2009, 197(1):35-40.
67. Varvel S.A., Bridgen D.T., Tao Q., Thomas B.F., Martin B.R., Lichtman A.H. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol ExpTher 2005, 314:329-337.
68. Varvel S.A., Wiley J.L., Yang R., Bridgen D.T., Long K., Lichtman A.H., et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 2006, 186:226-234.
69. Witkin J., Tzavara E., Davis R., Li X., Nomikos G. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci 2005, 26:609-617.